162 related articles for article (PubMed ID: 31726777)
1. A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer.
Vankova P; Salido E; Timson DJ; Man P; Pey AL
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31726777
[TBL] [Abstract][Full Text] [Related]
2. Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands.
Medina-Carmona E; Palomino-Morales RJ; Fuchs JE; Padín-Gonzalez E; Mesa-Torres N; Salido E; Timson DJ; Pey AL
Sci Rep; 2016 Feb; 6():20331. PubMed ID: 26838129
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL; Megarity CF; Timson DJ
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
[TBL] [Abstract][Full Text] [Related]
4. Thermodynamics of cooperative binding of FAD to human NQO1: Implications to understanding cofactor-dependent function and stability of the flavoproteome.
Clavería-Gimeno R; Velazquez-Campoy A; Pey AL
Arch Biochem Biophys; 2017 Dec; 636():17-27. PubMed ID: 29100982
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity.
Megarity CF; Timson DJ
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31431515
[TBL] [Abstract][Full Text] [Related]
6. Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase(1.).
Lienhart WD; Gudipati V; Uhl MK; Binter A; Pulido SA; Saf R; Zangger K; Gruber K; Macheroux P
FEBS J; 2014 Oct; 281(20):4691-4704. PubMed ID: 25143260
[TBL] [Abstract][Full Text] [Related]
7. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.
Asher G; Dym O; Tsvetkov P; Adler J; Shaul Y
Biochemistry; 2006 May; 45(20):6372-8. PubMed ID: 16700548
[TBL] [Abstract][Full Text] [Related]
8. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).
Megarity CF; Abdel-Aal Bettley H; Caraher MC; Scott KA; Whitehead RC; Jowitt TA; Gutierrez A; Bryce RA; Nolan KA; Stratford IJ; Timson DJ
Chembiochem; 2019 Nov; 20(22):2841-2849. PubMed ID: 31165578
[TBL] [Abstract][Full Text] [Related]
9. NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms.
Beaver SK; Mesa-Torres N; Pey AL; Timson DJ
Biochim Biophys Acta Proteins Proteom; 2019; 1867(7-8):663-676. PubMed ID: 31091472
[TBL] [Abstract][Full Text] [Related]
10. A mechanism for cancer-associated inactivation of NQO1 due to P187S and its reactivation by the consensus mutation H80R.
Muñoz IG; Morel B; Medina-Carmona E; Pey AL
FEBS Lett; 2017 Sep; 591(18):2826-2835. PubMed ID: 28771686
[TBL] [Abstract][Full Text] [Related]
11. Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism.
Medina-Carmona E; Neira JL; Salido E; Fuchs JE; Palomino-Morales R; Timson DJ; Pey AL
Sci Rep; 2017 Mar; 7():44532. PubMed ID: 28291250
[TBL] [Abstract][Full Text] [Related]
12. FAD-deficient P187S mutation of NAD(P)H:quinone oxidoreductase 1 (NQO1*2) binds and accelerates β-amyloid aggregation.
Panja S; Siegel D; Camandola S; de Cabo R; Ross D; Mallela KMG
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281795
[TBL] [Abstract][Full Text] [Related]
13. A small molecule chaperone rescues the stability and activity of a cancer-associated variant of NAD(P)H:quinone oxidoreductase 1 in vitro.
Strandback E; Lienhart WD; Hromic-Jahjefendic A; Bourgeois B; Högler A; Waltenstorfer D; Winkler A; Zangger K; Madl T; Gruber K; Macheroux P
FEBS Lett; 2020 Feb; 594(3):424-438. PubMed ID: 31605637
[TBL] [Abstract][Full Text] [Related]
14. A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1.
Moscovitz O; Tsvetkov P; Hazan N; Michaelevski I; Keisar H; Ben-Nissan G; Shaul Y; Sharon M
Mol Cell; 2012 Jul; 47(1):76-86. PubMed ID: 22793692
[TBL] [Abstract][Full Text] [Related]
15. Anion-specific interaction with human NQO1 inhibits flavin binding.
Pey AL
Int J Biol Macromol; 2019 Apr; 126():1223-1233. PubMed ID: 30615965
[TBL] [Abstract][Full Text] [Related]
16. Affinity-based small fluorescent probe for NAD(P)H:quinone oxidoreductase 1 (NQO1). Design, synthesis and pharmacological evaluation.
Bian J; Li X; Xu L; Wang N; Qian X; You Q; Zhang X
Eur J Med Chem; 2017 Feb; 127():828-839. PubMed ID: 27829520
[TBL] [Abstract][Full Text] [Related]
17. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1.
Asher G; Bercovich Z; Tsvetkov P; Shaul Y; Kahana C
Mol Cell; 2005 Mar; 17(5):645-55. PubMed ID: 15749015
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation compromises FAD binding and intracellular stability of wild-type and cancer-associated NQO1: Insights into flavo-proteome stability.
Medina-Carmona E; Rizzuti B; Martín-Escolano R; Pacheco-García JL; Mesa-Torres N; Neira JL; Guzzi R; Pey AL
Int J Biol Macromol; 2019 Mar; 125():1275-1288. PubMed ID: 30243998
[TBL] [Abstract][Full Text] [Related]
19. Structural dynamics and functional cooperativity of human NQO1 by ambient temperature serial crystallography and simulations.
Grieco A; Boneta S; Gavira JA; Pey AL; Basu S; Orlans J; Sanctis D; Medina M; Martin-Garcia JM
Protein Sci; 2024 Apr; 33(4):e4957. PubMed ID: 38501509
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).
Nolan KA; Doncaster JR; Dunstan MS; Scott KA; Frenkel AD; Siegel D; Ross D; Barnes J; Levy C; Leys D; Whitehead RC; Stratford IJ; Bryce RA
J Med Chem; 2009 Nov; 52(22):7142-56. PubMed ID: 19877692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
